Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05401955
Other study ID # Interventional
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 1, 2022
Est. completion date July 30, 2023

Study information

Verified date May 2022
Source University of Salamanca
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Range of motion, antropometric measurements, quality of life questionnaire and 2 minutes walk test will be implemented as an initial assessment. Physical exercise program will take 2 sessions a week for six months, and several follow-ups: before, during and after treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 12
Est. completion date July 30, 2023
Est. primary completion date May 10, 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Allogenic Transplantation patients with Graft versus host disease Exclusion Criteria: - Cognitive impairment - Physical limitation from other pathologies

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Physical exercise
An adapted physical exercise protocol

Locations

Country Name City State
Spain University of Salamanca Salamanca

Sponsors (1)

Lead Sponsor Collaborator
University of Salamanca

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary SF36 Questionnaire Quality of life baseline and post-intervention (24 weeks)
Primary 2 minutes walk test walking for 2 minutes without rest baseline and post-intervention (24 weeks)
Primary Hands strength Dynamometer baseline and post-intervention (24 weeks)
Primary Active range of motion P-ROM. Active ROM will be compared with standard pictures (1-4 points for lower limb and 1-7 points for upper limb) baseline and post-intervention (24 weeks)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05855707 - Wharton Jelly Mesenchymal Stromal Cells as GVHD Prophylaxis Phase 1
Active, not recruiting NCT04522843 - Analysis of Intestinal Defensin Expression in Acute GVHD
Recruiting NCT05718791 - CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease
Recruiting NCT05368181 - MAP-guided Preemptive Therapy of aGvHD Phase 2
Withdrawn NCT05443464 - Mesenchymal Stem Cells (MSCs) for Steroid Refractory Acute GVHD (SR-aGVHD) Phase 1
Not yet recruiting NCT06315309 - Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant Phase 2
Terminated NCT04220632 - A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease Phase 1/Phase 2
Recruiting NCT04284904 - Role of aGVHD Biomarkers on aGVHD Risks
Not yet recruiting NCT06164288 - Safety and Efficacy Study of hAESCs Therapy for aGVHD Phase 1
Recruiting NCT06462365 - Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) Phase 1